Summit debuts longer-term ivonescimab data as it awaits FDA NSCLC decision

Summit Therapeutics has released more Phase III trial data for ivonescimab in non-small cell lung cancer (NSCLC) as it awaits ...

FDA Grants Priority Review for Pfizer’s TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer

(NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for Priority Review a supplemental New Drug Application (sNDA) for TALZENNA ® (talazoparib), an oral poly ...

With FDA approval, Celcuity sees big future for its new breast cancer drug

Brian Sullivan, CEO of Plymouth, Minnesota-based Celcuity, is convinced his biotech startup will soon provide the new standard of care for tens of thousands of breast cancer patients. Last week, ...

FDA Accepts RVMD's Filing for Daraxonrasib in Pancreatic Cancer

Revolution Medicines' FDA filing for daraxonrasib in metastatic pancreatic cancer enters an accelerated review program, ...
KMTV 3 News Now

New pancreatic cancer drug that doubles survival time now available at Nebraska Medicine

A new drug is doubling survival time for pancreatic cancer patients. Daraxonrasib, the drug being taken by former Sen. Ben ...
AFRO American Newspapers

The fight against sarcoma: Black patients push for earlier detection and better research

July is Sarcoma Awareness Month and according to Cleveland Clinic, sarcoma accounts for about 1 percent of adult cancers but 15 percent to 20 percent of childhood cancers. The Black community speaks ...
Zacks Investment Research on MSN

SMMT shares updated Ivonescimab survival data from NSCLC study

Summit Therapeutics SMMT announced updated overall survival ("OS") data from the phase III HARMONi study evaluating its investigational antibody ivonescimab in certain patients with non-small cell ...